TrialThe Lancet. Oncology2025

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Jian Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.